tooluniverse-antibody-engineering

# Antibody Engineering & Optimization

AI-guided antibody optimization pipeline from preclinical lead to clinical candidate. Covers sequence humanization, structure modeling, affinity optimization, developability assessment, immunogenicity prediction, and manufacturing feasibility.

**KEY PRINCIPLES**:
1. **Report-first approach** - Create optimization report before analysis
2. **Evidence-graded humanization** - Score based on germline alignment and framework retention
3. **Developability-focused** - Assess aggregation, stability, PTMs, immunogenicity
4. **Structure-guided** - Use AlphaFold/PDB structures for CDR analysis
5. **Clinical precedent** - Reference approved antibodies for validation
6. **Quantitative scoring** - Developability score (0-100) combining multiple factors
7. **English-first queries** - Always use English terms in tool calls, even if user writes in another language. Respond in user's language

---

## LOOK UP, DON'T GUESS
When uncertain about any scientific fact, SEARCH databases first (PubMed, UniProt, ChEMBL, ClinVar, etc.) rather than reasoning from memory. A database-verified answer is always more reliable than a guess.

---

## When to Use

Apply when user asks:
- "Humanize this mouse antibody sequence"
- "Optimize antibody affinity for [target]"
- "Assess developability of this antibody"
- "Predict immunogenicity risk for [sequence]"
- "Engineer bispecific antibody against [targets]"
- "Reduce aggregation in antibody formulation"
- "Design pH-dependent binding antibody"
- "Analyze CDR sequences and suggest mutations"

---

## Critical Workflow Requirements

### 1. Report-First Approach (MANDATORY)

1. **Create the report file FIRST**: `antibody_optimization_report.md`
2. **Progressively update** as analysis completes
3. **Output separate files**:
   - `optimized_sequences.fasta` - All optimized variants
   - `humanization_comparison.csv` - Before/after comparison
   - `developability_assessment.csv` - Detailed scores

See `REPORT_TEMPLATE.md` for the full report template with section formats.

### 2. Documentation Standards (MANDATORY)

Every optimization MUST include per-variant documentation with:
- Original and optimized sequences
- Humanization score (% human framework)
- CDR preservation confirmation
- Metrics table (humanness, aggregation risk, predicted KD, immunogenicity)
- Data source citations

---

## Phase 0: Tool Verification

### Required Tools

| Tool | Purpose | Category |
|------|---------|----------|
| `IMGT_search_genes` | Germline gene identification | Humanization |
| `IMGT_get_sequence` | Human framework sequences | Humanization |
| `SAbDab_search_structures` | Antibody structure precedents | Structure |
| `TheraSAbDab_search_by_target` | Clinical antibody benchmarks | Validation |
| `alphafold_get_prediction` | Structure modeling | Structure |
| `iedb_search_epitopes` | Epitope identification | Immunogenicity |
| `iedb_search_bcell` | B-cell epitope prediction | Immunogenicity |
| `UniProt_get_entry_by_accession` | Target antigen information | Target |
| `STRING_get_interaction_partners` | Protein interaction network | Bispecifics |
| `PubMed_search_articles` | Literature precedents | Validation |

**CRITICAL**: SOAP tools (IMGT, SAbDab, TheraSAbDab) require an `operation` parameter. See `QUICK_START.md` for correct usage.

---

## Workflow Overview

```
Phase 1: Input Analysis & Characterization
├── Sequence annotation (CDRs, framework)
├── Species identification
├── Target antigen identification
├── Clinical precedent search
└── OUTPUT: Input characterization
    ↓
Phase 2: Humanization Strategy
├── Germline gene alignment (IMGT)
├── Framework selection
├── CDR grafting design
├── Backmutation identification
└── OUTPUT: Humanization plan
    ↓
Phase 3: Structure Modeling & Analysis
├── AlphaFold prediction
├── CDR conformation analysis
├── Epitope mapping
├── Interface analysis
└── OUTPUT: Structural assessment
    ↓
Phase 4: Affinity Optimization
├── In silico mutation screening
├── CDR optimization strategies
├── Interface improvement
└── OUTPUT: Affinity variants
    ↓
Phase 5: Developability Assessment
├── Aggregation propensity
├── PTM site identification
├── Stability prediction
├── Expression prediction
└── OUTPUT: Developability score
    ↓
Phase 6: Immunogenicity Prediction
├── MHC-II epitope prediction (IEDB)
├── T-cell epitope risk
├── Aggregation-related immunogenicity
└── OUTPUT: Immunogenicity risk score
    ↓
Phase 7: Manufacturing Feasibility
├── Expression level prediction
├── Purification considerations
├── Formulation stability
└── OUTPUT: Manufacturing assessment
    ↓
Phase 8: Final Report & Recommendations
├── Ranked variant list
├── Experimental validation plan
├── Next steps
└── OUTPUT: Comprehensive report
```

---

## Phase 1: Input Analysis & Characterization

**Goal**: Annotate sequences, identify species/germline, find clinical precedents.

**Key steps**:
1. Annotate CDRs using IMGT numbering (CDR-H1: 27-38, CDR-H2: 56-65, CDR-H3: 105-117)
2. Identify closest human germline genes via `IMGT_search_genes`
3. Search clinical precedents via `TheraSAbDab_search_by_target`
4. Get target antigen info via `UniProt_get_entry_by_accession`

**Output**: Sequence information table, CDR annotation, target info, clinical precedent list.

See `WORKFLOW_DETAILS.md` Phase 1 for code examples.

---

## Phase 2: Humanization Strategy

**Goal**: Select human framework, design CDR grafting, identify backmutations.

**Key steps**:
1. Search IMGT for IGHV/IGKV human germline genes
2. Score candidate frameworks by identity, CDR compatibility, and clinical use
3. Design CDR grafting onto selected framework
4. Identify Vernier zone residues that may need backmutation (positions 2, 27-30, 47-48, 67, 69, 71, 78, 93-94)
5. Generate at least 2 variants: full humanization and with key backmutations
6. Calculate humanization score (framework humanness, CDR preservation, T-cell epitopes, aggregation risk)

**Output**: Framework selection